69 related articles for article (PubMed ID: 35445677)
1.
Pei M; Li H; Zhu Y; Lu J; Zhang C
Biomater Sci; 2022 May; 10(11):2865-2876. PubMed ID: 35445677
[TBL] [Abstract][Full Text] [Related]
2. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
3. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines.
Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z
Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438
[TBL] [Abstract][Full Text] [Related]
4. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
Yip T; Qi X; Yan H; Chang Y
ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
[TBL] [Abstract][Full Text] [Related]
5. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
[TBL] [Abstract][Full Text] [Related]
6. CpG-Based Nanovaccines for Cancer Immunotherapy.
Chen W; Jiang M; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
Int J Nanomedicine; 2021; 16():5281-5299. PubMed ID: 34385817
[TBL] [Abstract][Full Text] [Related]
7. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
8. DNA-inorganic hybrid nanovaccine for cancer immunotherapy.
Zhu G; Liu Y; Yang X; Kim YH; Zhang H; Jia R; Liao HS; Jin A; Lin J; Aronova M; Leapman R; Nie Z; Niu G; Chen X
Nanoscale; 2016 Mar; 8(12):6684-92. PubMed ID: 26947116
[TBL] [Abstract][Full Text] [Related]
9. Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy.
Liu M; Feng Y; Lu Y; Huang R; Zhang Y; Zhao Y; Mo R
Sci Adv; 2024 Mar; 10(11):eadk2444. PubMed ID: 38478602
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy.
Shi C; Jian C; Wang L; Gao C; Yang T; Fu Z; Wu T
J Nanobiotechnology; 2023 Sep; 21(1):347. PubMed ID: 37752555
[TBL] [Abstract][Full Text] [Related]
11. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy.
Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J
ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021
[TBL] [Abstract][Full Text] [Related]
12. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
13. Biologically Self-Assembled Tumor Cell-Derived Cancer Nanovaccines as an All-in-One Platform for Cancer Immunotherapy.
Liang K; Sun Y; Xie L; Liu Y; You Y; Xu J; Ma F; Huang Y; Song Q; Xiao W; Huang J; Gao X; Chen J
ACS Nano; 2024 Feb; 18(8):6702-6717. PubMed ID: 38359389
[TBL] [Abstract][Full Text] [Related]
14. Antigen Self-Presented Personalized Nanovaccines Boost the Immunotherapy of Highly Invasive and Metastatic Tumors.
Wang T; Han M; Han Y; Jiang Z; Zheng Q; Zhang H; Li Z
ACS Nano; 2024 Feb; 18(8):6333-6347. PubMed ID: 38349234
[TBL] [Abstract][Full Text] [Related]
15. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy.
Zhang H; Xia X
Hum Vaccin Immunother; 2021 Sep; 17(9):2995-2998. PubMed ID: 33945399
[TBL] [Abstract][Full Text] [Related]
16. Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.
Kakwere H; Ingham ES; Allen R; Mahakian LM; Tam SM; Zhang H; Silvestrini MT; Lewis JS; Ferrara KW
Bioconjug Chem; 2017 Nov; 28(11):2756-2771. PubMed ID: 28956907
[TBL] [Abstract][Full Text] [Related]
17. A Universal Cyclodextrin-Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity.
Mao J; Jin Z; Rui X; Li L; Hou C; Leng X; Bi X; Chen Z; Chen Y; Wang J
Adv Healthc Mater; 2023 Oct; 12(27):e2301099. PubMed ID: 37602523
[TBL] [Abstract][Full Text] [Related]
18. In Situ Cocktail Nanovaccine for Cancer Immunotherapy.
Liu M; Xie D; Hu D; Zhang R; Wang Y; Tang L; Zhou B; Zhao B; Yang L
Adv Sci (Weinh); 2023 Nov; 10(31):e2207697. PubMed ID: 37740439
[TBL] [Abstract][Full Text] [Related]
19. Peptide-Decorated Degradable Polycarbonate Nanogels for Eliciting Antigen-Specific Immune Responses.
Stickdorn J; Czysch C; Medina-Montano C; Stein L; Xu L; Scherger M; Schild H; Grabbe S; Nuhn L
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895096
[TBL] [Abstract][Full Text] [Related]
20. A novel fluoropolymer as a protein delivery vector with robust adjuvant effect for cancer immunotherapy.
Zhan YR; He X; Huang ZY; Chen P; Tian MM; Li GH; Yu XQ; Song XR; Zhang J
J Mater Chem B; 2023 Sep; 11(37):8933-8942. PubMed ID: 37682063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
